Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of genomic background and developmental state on signaling pathways and response to therapy in glioblastoma patient-derived cells.
Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K, Irtenkauf S, Hasselbach L, Meng Y, Mueller C, Petricoin EF, Brown S, Purandare N, Aras S, Mikkelsen T, Poisson L, Noushmehr H, Ruden D, deCarvalho AC. Berezovsky A, et al. Among authors: petricoin ef. bioRxiv [Preprint]. 2024 Sep 23:2024.03.14.585115. doi: 10.1101/2024.03.14.585115. bioRxiv. 2024. PMID: 39386580 Free PMC article. Preprint.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM; I-SPY2 Investigators; Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Campbell MJ, et al. Among authors: petricoin ef. Cell Rep Med. 2024 Nov 19;5(11):101799. doi: 10.1016/j.xcrm.2024.101799. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510069 Free PMC article.
Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.
Elias AD, Staley AW, Fornier M, Vidal GA, Alami V, Sams S, Spoelstra NS, Goodspeed A, Kabos P, Diamond JR, Shagisultanova E, Gallagher RI, Wulfkuhle JD, Petricoin EF, Zolman KL, McSpadden T, Jordan KR, Slansky JE, Borges VF, Gao D, Richer JK. Elias AD, et al. Among authors: petricoin ef. NPJ Breast Cancer. 2024 Oct 6;10(1):88. doi: 10.1038/s41523-024-00697-5. NPJ Breast Cancer. 2024. PMID: 39368973 Free PMC article.
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Klomp JE, Diehl JN, Klomp JA, Edwards AC, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A, Johnson JL, Huntsman EM, Yaron TM, Pierobon M, Baldelli E, Prevatte AW, Barker NK, Herring LE, Petricoin EF 3rd, Graves LM, Cantley LC, Cox AD, Der CJ, Stalnecker CA. Klomp JE, et al. Among authors: petricoin ef 3rd. Science. 2024 Jun 7;384(6700):eadk0850. doi: 10.1126/science.adk0850. Epub 2024 Jun 7. Science. 2024. PMID: 38843329 Free PMC article.
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.
Nussbaum DP, Martz CA, Waters AM, Barrera A, Liu A, Rutter JC, Cerda-Smith CG, Stewart AE, Wu C, Cakir M, Levandowski CB, Kantrowitz DE, McCall SJ, Pierobon M, Petricoin EF 3rd, Joshua Smith J, Reddy TE, Der CJ, Taatjes DJ, Wood KC. Nussbaum DP, et al. Among authors: petricoin ef 3rd. NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9. NPJ Precis Oncol. 2024. PMID: 38822082 Free PMC article.
Keratin 17 modulates the immune topography of pancreatic cancer.
Delgado-Coka L, Horowitz M, Torrente-Goncalves M, Roa-Peña L, Leiton CV, Hasan M, Babu S, Fassler D, Oentoro J, Bai JK, Petricoin EF 3rd, Matrisian LM, Blais EM, Marchenko N, Allard FD, Jiang W, Larson B, Hendifar A, Chen C, Abousamra S, Samaras D, Kurc T, Saltz J, Escobar-Hoyos LF, Shroyer KR. Delgado-Coka L, et al. Among authors: petricoin ef 3rd. J Transl Med. 2024 May 10;22(1):443. doi: 10.1186/s12967-024-05252-1. J Transl Med. 2024. PMID: 38730319 Free PMC article.
Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Bateman NW, Abulez T, Soltis AR, McPherson A, Choi S, Garsed DW, Pandey A, Tian C, Hood BL, Conrads KA, Teng PN, Oliver J, Gist G, Mitchell D, Litzi TJ, Tarney CM, Crothers BA, Mhawech-Fauceglia P, Dalgard CL, Wilkerson MD, Pierobon M, Petricoin EF, Yan C, Meerzaman D, Bodelon C, Wentzensen N, Lee JSH; APOLLO Research Network; Huntsman DG, Shah S, Shriver CD, Phippen NT, Darcy KM, Bowtell DDL, Conrads TP, Maxwell GL. Bateman NW, et al. Among authors: petricoin ef. NPJ Precis Oncol. 2024 May 6;8(1):97. doi: 10.1038/s41698-024-00588-9. NPJ Precis Oncol. 2024. PMID: 38710993 Free PMC article. No abstract available.
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van ˈt Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM. Wescott EC, et al. Among authors: petricoin ef. Cancer Res Commun. 2024 Apr 24;4(4):1120-1134. doi: 10.1158/2767-9764.CRC-23-0468. Cancer Res Commun. 2024. PMID: 38687247 Free PMC article.
Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF 3rd, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF. Delgado-Coka LA, et al. Among authors: petricoin ef 3rd. Am J Clin Pathol. 2024 Sep 3;162(3):314-326. doi: 10.1093/ajcp/aqae038. Am J Clin Pathol. 2024. PMID: 38642081 Free PMC article.
382 results